We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
+$28.4M
(+1.3%)
Cap. Flow
-$577M
Cap. Flow
% of AUM
-26.84%
Top 10 Holdings %
Top 10 Hldgs %
29.86%
Holding
143
New
30
Increased
17
Reduced
35
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
|
+$75.8M |
| 2 |
THOR
THORATEC CORPORATION
THOR
|
+$31.1M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$30.7M |
| 4 |
Viatris
VTRS
|
+$27.4M |
| 5 |
Traws Pharma
TRAW
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
|
+$43.8M |
| 2 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$42.7M |
| 3 |
Nektar Therapeutics
NKTR
|
+$34M |
| 4 |
STJ
St Jude Medical
STJ
|
+$24M |
| 5 |
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
|
+$23.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.2% |
| 2 | Technology | 1.35% |
| 3 | Financials | 1.05% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ASRT
51
DELISTED
Assertio
ASRT
| $11.2M | 0.52% |
25,083
| – | – |
|
52
Option Care Health
OPCH
$3.41B
| $11M | 0.51% |
+312,260
| New | +$17.1M |
|
|
NSPH
53
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $10.3M | 0.48% |
+257,161
| New | +$12.8M |
|
|
LITS
54
Lite Strategy Inc
LITS
$33.6M
| $9.25M | 0.43% |
41,110
| – | – |
|
|
CEMP
55
DELISTED
Cempra, Inc.
CEMP
| $9.24M | 0.43% |
803,516
-802,994
| -50% | -$7.04M |
|
56
Vanda Pharmaceuticals
VNDA
$327M
| $8.98M | 0.42% |
+820,000
| New | +$8.76M |
|
|
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
| $8.3M | 0.39% |
560,331
+79,259
| +16% | +$1.06M |
|
58
Cross Country Healthcare
CCRN
$428M
| $8.12M | 0.38% |
1,343,464
-238,763
| -15% | -$1.37M |
|
59
Alphatec Holdings
ATEC
$1.31B
| $7.85M | 0.36% |
331,895
+25,845
| +8% | +$655K |
|
|
LPDX
60
DELISTED
LIPOSCIENCE INC COM
LPDX
| $6.91M | 0.32% |
1,382,350
+279,606
| +25% | +$1.57M |
|
|
ANTH
61
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $6.8M | 0.32% |
211,482
-5,603
| -3% | -$174K |
|
|
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.41M | 0.3% |
121,658
-135,201
| -53% | -$9.08M |
|
63
Tempest Therapeutics
TPST
$15.4M
| $6.02M | 0.28% |
208
+18
| +9% | +$639K |
|
|
64
CALL
Viatris
VTRS
$20.1B
| $5.73M | 0.27% |
+150,000
| New | +$5.28M |
|
|
NSTG
65
DELISTED
NanoString Technologies, Inc.
NSTG
| $5.46M | 0.25% |
+496,650
| New | +$4.49M |
|
|
AIRM
66
CALL
DELISTED
Air Methods Corp
AIRM
| $5.32M | 0.25% |
+125,000
| New | +$4.8M |
|
67
PUT
Sarepta Therapeutics
SRPT
$1.82B
| $4.72M | 0.22% |
+100,000
| New | +$3.85M |
|
|
CASM
68
DELISTED
CAS Medical Systems, Inc.
CASM
| $4.29M | 0.2% |
+3,200,000
| New | +$4.7M |
|
|
FRX
69
CALL
DELISTED
FOREST LABORATORIES INC
FRX
| $4.28M | 0.2% |
100,000
| – | – |
|
70
Agios Pharmaceuticals
AGIO
$2.36B
| $4.22M | 0.2% |
+151,050
| New | +$4.17M |
|
|
ESRX
71
DELISTED
Express Scripts Holding Company
ESRX
| $4.02M | 0.19% |
+65,000
| New | +$4.2M |
|
72
Rigel Pharmaceuticals
RIGL
$750M
| $3.82M | 0.18% |
106,773
-164,232
| -61% | -$5.99M |
|
73
TherapeuticsMD
TXMD
$23.8M
| $3.66M | 0.17% |
+25,000
| New | +$3.02M |
|
74
Novavax
NVAX
$1.35B
| $3.39M | 0.16% |
+53,849
| New | +$3.03M |
|
|
PTLA
75
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.19M | 0.15% |
119,448
-407,962
| -77% | -$9.71M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2013 Portfolio in Review
As of Q3 2013, Deerfield Management held 143 positions worth $2.15B, up 1.3% from $2.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Deerfield Management withdrew a net $577M in Q3 2013, closing 30 positions and reducing 35 holdings. Its most notable exit was OPTIMER PHARMACEUTICALS, INC. COM STK, an estimated $43.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.
Against the trend, Deerfield Management opened a new position in PROSENSA HLDGS N V ORD SHS (NLD) worth $21.3M.
- Deerfield Management's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 3,224,524 shares worth $21.3M.
- Deerfield Management added most to Spectrum Pharmaceuticals Inc in Q3 2013, an estimated $24.3M increase.
- Deerfield Management's biggest Q3 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $42.7M.
- Deerfield Management fully exited OPTIMER PHARMACEUTICALS, INC. COM STK in Q3 2013, selling an estimated $43.8M.
- Deerfield Management's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2013.
- Deerfield Management opened 30 new positions and closed 30 in Q3 2013.
- Deerfield Management's portfolio value rose 1.3% quarter-over-quarter to $2.15B.
Based on Deerfield Management's 13F filing for Q3 2013, filed 14 Nov 2013.